Relatively higher risk of Guillain-Barre Syndrome (GBS) after Janssen #COVID19 #Vaccine
1. Within 21 days of vaccination, GBS reporting rates per 1 million doses were 3.29 for the Janssen vaccine versus 0.29 and 0.35 for the Pfizer and Moderna vaccines, respectively
#MedTwitter
1. Within 21 days of vaccination, GBS reporting rates per 1 million doses were 3.29 for the Janssen vaccine versus 0.29 and 0.35 for the Pfizer and Moderna vaccines, respectively
#MedTwitter
2. Within 42 days of vaccination, reporting rates per 1 million doses were 4.07, 0.34, and 0.44, respectively for Janssen, Pfizer and Moderna vaccines.
jamanetwork.com)%3Ae2253845.%20doi%3A-,10.1001/jamanetworkopen.2022.53845,-COVID%2D19%20Resource
jamanetwork.com)%3Ae2253845.%20doi%3A-,10.1001/jamanetworkopen.2022.53845,-COVID%2D19%20Resource
3. The Advisory Committee on Immunization Practices (ACIP) preferentially recommends that people age 18 years and older receive an mRNA COVID-19 vaccine rather than the Janssen adenoviral vector vaccine when both types of COVID-19 vaccine are available.
4. GBS is an immune-mediated neurological disease, which results in weakness of legs & arms, speech & swallowing impairment, and respiratory muscle paralysis (in severe cases). Treatment requires IV immunoglobulin injections or plasma exchange therapy.
Loading suggestions...